JNJ-39758979 / J&J - LARVOL DELTA

Histamine 2 Receptor Agonism and Histamine 4 Receptor Antagonism Ameliorate Inflammation in a Model of Psoriasis. (PubMed, Acta Derm Venereol) - "The aim of this study was to test the role of histamine 2 receptors and histamine 4 receptors in the imiquimod-induced psoriasis-like skin inflammation model. The combination of amthamine and JNJ-39758979 reduced skin inflammation even more pronounced, diminished epidermal hyperproliferation, and inhibited spontaneous scratching behaviour. A combination of histamine 2 receptor agonist and histamine 4 receptor antagonists could represent a new strategy for the treatment of psoriasis."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis

A study of JNJ-39758979 in adult Japanese patients with moderate atopic dermatitis (clinicaltrials.gov) - P2, N=88; Recruiting -> Terminated (Terminated prematurely due to 2 cases of agranulocytosis); N=105 -> 88

Trial terminated • Eczema • Immunology

Oral small molecules for the treatment of atopic dermatitis: a systematic review. (PubMed, J Dermatolog Treat) - "Preliminary results demonstrate that oral small molecules are an effective treatment option in AD with minimal side effects. Additional randomized studies with larger sample sizes are needed to determine the efficacy and long-term side effects of these novel therapies."

Journal • Review

Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of an H R-antagonist (JNJ-39758979) in adults with uncontrolled asthma. (PubMed, Clin Exp Allergy) - P2; "The findings suggest potential benefit of H R antagonists on lung function and asthma control in eosinophilic asthma patients and warrant further evaluation of this mechanism in asthma with eosinophilic inflammation. NCT00946569."

Clinical • Journal • P2a data